Cancer Drug Shortages: Why the ASCO and FDA Resource Pages Matter

What a shortage officially is

The law gives "drug shortage" a precise meaning. It is a period when demand for a drug in the United States is greater than the supply.

The FDA tracks this at the national level. Makers tell the agency what they are able to supply. A drug counts as being in shortage when, across the country, supply is not meeting demand now or is not expected to meet it soon.

That word "nationwide" is the one that matters most to a patient reading a headline. A drug your pharmacy cannot get today may not be in a national shortage at all.

Why it keeps happening to cancer drugs

The FDA says quality problems in making the drug are the most common cause. Other causes include delays in production, waits for raw materials, sudden jumps in demand, and firms simply stopping.

The agency then points to a weak spot that hits cancer care hard.

Many cancer regimens use older sterile injectable drugs. Few firms still make them. That leaves only a handful of production lines. The suppliers of raw materials are limited too. These drugs are hard to make and take a long time to produce. So when one company has a problem, the others cannot step up quickly.

The FDA also notes that it cannot force a firm to keep making a drug. Older drugs are sometimes dropped in favor of newer ones that earn more.

So the drugs most at risk are often the cheap, decades-old, backbone chemotherapies — not the expensive new arrivals.

A shortage is not a medical finding

This is worth separating out clearly. A shortage is not a discovery about a drug. Nothing about the medicine has changed, and nothing about your cancer has changed.

It is a failure of supply, not of science. The medicine still works as well as it did last month.

What changes is logistics. A team may check local stock, use an alternative backed by evidence, shift timing, or send someone to another site. They may also rank who needs the limited supply most. ASCO's guidance stresses two things here: alternatives backed by evidence, and decisions made by the whole team.

Local versus national

The FDA speaks to this directly. It gets reports from hospitals, pharmacies, patients, and clinicians about local supply gaps. It says these are usually brief. They often come down to how the drug was shipped, not how it was made, and they clear once the pharmacy can reorder.

Its advice is plain. If you cannot find a medicine locally, it may be a short-term local issue. Check other pharmacies. Ask your provider or pharmacist about an alternative.

Anyone can report a suspected shortage. The FDA takes reports from health professionals, patients, and professional groups through an online portal.

How to read the two resource pages

The FDA database lists drugs as available, in shortage, resolved, or stopped. The maker listed for an entry can change. It is a national list. It is not a statement about your center, and it is not a treatment plan.

ASCO's pages are written mainly for cancer teams. They gather clinical guidance, policy news, and resources by disease. For a patient, they help explain the thinking behind a decision. The decision itself still rests on cancer type, stage, the goal of treatment, what else is available, and local supply.

Neither page can tell you whether your own infusion next Tuesday is affected. Only your team can.

What to ask, and when

If you hear about a shortage, ask targeted questions rather than trying to interpret national lists yourself:

• Is any medicine in my current plan affected?
• If so, is the shortage at this center, in this region, or national?
• Is there an equivalent or evidence-supported alternative for my situation?
• Would a change in timing, dose, or sequence affect the goal of my treatment?
• Who will contact me if my appointment or infusion plan changes, and how much notice will I get?
• Is there anyone here who helps with access and coverage problems?

Contact your team promptly — rather than waiting for your next scheduled visit — if:

• A pharmacy tells you an oral cancer drug cannot be filled.
• You are told an infusion is being postponed and no new date is given.
• You have missed a dose of any cancer medicine for any reason.
• You are offered a substitute and were not told what it is or why.

Do not stretch doses, split tablets, or skip treatment to make a supply last. Our page on chemotherapy covers what to establish before a regimen starts, and our guide to costs and insurance in clinical trials covers the access side if a trial becomes part of the discussion.

What this does not mean

• It does not mean every cancer drug is in shortage. Most are not.
• It does not mean your plan has changed unless your team says it has.
• It does not mean patients should skip doses, stretch medicines, or delay treatment without medical guidance.
• It does not mean every alternative regimen is equivalent for every patient.
• It does not mean a problem is only local. Some shortages are national; others are temporary or regional.
• Shortage listings change frequently, so a page checked on one date may not reflect today's position.

Sources

• American Society of Clinical Oncology, Drug Shortages: https://www.asco.org/practice-patients/practice-support/drug-shortages
• American Society of Clinical Oncology, Drug Shortages — Clinical Guidance: https://www.asco.org/practice-patients/practice-support/drug-shortages/clinical-guidance
• U.S. Food and Drug Administration, Drug Shortages: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
• U.S. Food and Drug Administration, Frequently Asked Questions about Drug Shortages: https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
• National Cancer Institute, Cancer Treatment: https://www.cancer.gov/about-cancer/treatment

How this page was made

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

See an error, old source, or unclear wording? Tell us.